Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05365763 · ClinicalTrials.gov registry record

Developing an Experimental Framework to Evaluate Oncologist Emotion Regulation

A clinical trial of Communication, sponsored by Dartmouth-Hitchcock Medical Center.

Completed
Registry status
11
Enrollment target
1
Study location

NCT05365763: Completed study of Communication, sponsored by Dartmouth-Hitchcock Medical Center.

NCT05365763 is a study of Communication that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 11 participants, below the 1,421-participant average among 34 other Communication trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05365763, a study of Communication, has completed, sponsored by Dartmouth-Hitchcock Medical Center.

COMPLETED
Registry status
11 participants
Enrollment target
1
Study location

Study Summary

The research team recruited physicians (medical oncologists and specialty palliative care providers) trained in a communication tool called the serious illness conversation guide. Physicians conducted a simulated, telehealth serious illness conversation with an actor playing the role of a patient with advanced cancer. Physicians completed psychologic inventories before and after the encounter, documented the encounter using a template in the electronic medical record, and then participated in a structured interview afterwards discussing what they were feeling during the encounter and how it impacted the encounter. Physicians also wore three heart rate variability sensors during the simulated encounter.

Primary Outcome

This is a composite measure with four criteria: 1) \>60% approached clinicians enroll on study; 2) \<5% of missing time from encounter audio file; 3) \<20% of missing time from heart rate variability collection; and 4) survey completion rates \>90% of all items. All four criteria must be met for investigators to assess as feasible.

Conditions Studied

Interventions

  • BEHAVIORAL Simulated telehealth serious illness conversation visit

Study Locations (1)

New Hampshire

  • Dartmouth-Hitchcock Medical Center - Lebanon

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2020-05-01
Est. Completion 2021-09-30
Dartmouth-Hitchcock Medical Center

427 total trials

What the finished NCT05365763 record still lists

NCT05365763 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 1,421-participant average among 34 other Communication trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Communication appearing as the primary indexed condition, and to 1 intervention - of which Simulated telehealth serious illness conversation visit is the first listed.

NCT05365763 reports a single indexed study location in New Hampshire.

Frequently Asked Questions

What is clinical trial NCT05365763 about?

NCT05365763 is a clinical study titled "Developing an Experimental Framework to Evaluate Oncologist Emotion Regulation". The research team recruited physicians (medical oncologists and specialty palliative care providers) trained in a communication tool called the serious illness conversation guide. Physicians conducted a simulated, telehealth serious illness conversation with an actor playing the role of a patient wi...

What is the current status of trial NCT05365763?

This trial is currently completed. The enrollment target is 11 participants. The study started on 2020-05-01. Estimated completion is 2021-09-30.

What conditions does trial NCT05365763 study?

This clinical trial studies the following conditions: Communication.

What interventions are being tested in trial NCT05365763?

The interventions under investigation include: Simulated telehealth serious illness conversation visit (BEHAVIORAL).

Who is sponsoring clinical trial NCT05365763?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05365763 being conducted?

This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Communication

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05365763's enrollment target sits among peer trials

11 35th of 34 the lowest of 34 other Communication trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Communication trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05365763, the US trial registry maintained by the National Library of Medicine. NCT05365763 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.